Cardima Awarded Patent for a Guiding Catheter With Balloon to Access, Visualize and Deliver Other Devices Into the Veins in the Heart.

Business Editors/Health & Medical Writers

FREMONT, Calif.--(BUSINESS WIRE)--April 7, 2000

A new guiding catheter for accessing, visualizing and then delivering intravascular devices to the veins of a patient's heart was awarded a patent from the United States Patent and Trademark Office (USPTO), announced Cardima, Inc. (Nasdaq SC:CRDM) today.

"This patent is extremely important for Cardima," said Phillip Radlick, Ph.D., President and Chief Executive Officer of Cardima, "because it strengthens our intellectual property position with intravascular guiding and visualizing devices for accessing the veins of the heart. Historically, the rapid advances made in the treatment of coronary artery disease were made possible by products which could locate the arteries and show physicians their anatomy. The Cardima Vueport, on sale worldwide, opens access to the heart's musculature through the venous system. This previously neglected avenue allows physicians to visualize the venous structure and then, through the catheters lumen, place other devices in the wall of the heart. Thus physicians may be able to more easily diagnose or treat patients with poorly functioning hearts."

"There are many applications for such a guiding visualization device," continued Dr. Radlick, "for example a large percentage of the over 5 million people who suffer from heart failure may benefit from bi-ventricular pacing leads placed into the heart's coronary veins."

With this latest award from the US Patent Office, Cardima now has 22 patents awarded covering many aspects of the diagnosis and treatment of electrical disturbances of the heart.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include whether the Company will be able to defend its patents, complete clinical trials, gain necessary regulatory approvals and gain market acceptance for its products. Additional risks are set forth in Cardima's Annual Report on Form 10-K for December 31, 1999 filed with the Securities and Exchange Commission on March 30, 2000.